VZV Infection After Bone Marrow Transplantation Clinical Trial
Official title:
Randomized Trial of Long-Term Oral Acyclovir Usage to Prevent Varicella Zoster Virus Infection After Allogeneic Bone Marrow Transplant
The objective of this study is to prevent reactivation of herpes zoster during the first year after transplant.
Herpes zoster infection occurs in 30% of allogeneic hematopoietic cell transplant (HCT)
recipients who had a history of varicella zoster virus (VZV) infection. A safe and effective
prevention strategy has not been established.
77 marrow allograft recipients at risk for VZV reactivation were randomized to oral
acyclovir 800 mg twice daily or placebo given from day 30 until day 365 and were followed
for toxicity and clinical evidence of herpes zoster infection.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind